Description
Vildagliptin is an anti-diabetic drug that works by preventing the breakdown of incretin hormones, namely:
-
Glucagon-like peptide-1 (GLP-1)
-
Glucose-dependent insulinotropic peptide (GIP)
These hormones help control blood sugar levels, and Vildagliptin increases their levels to enhance glucose regulation.
Vildagliptin exerts its blood glucose-lowering effects by selectively inhibiting dipeptidyl peptidase-4 (DPP-4), an enzyme that inactivates GLP-1 and GIP. By inhibiting DPP-4, Vildagliptin significantly increases the half-life of GLP-1 and GIP, leading to higher levels of active incretin hormones.
The duration of DPP-4 inhibition by Vildagliptin is dose-dependent, helping reduce fasting and postprandial blood glucose and HbA1c levels. It enhances glucose sensitivity in alpha- and beta-cells and increases insulin production.
Key Benefits:
✔ Lowers fasting and postprandial glucose levels
✔ Improves lipid and lipoprotein metabolism
✔ Enhances insulin sensitivity
✔ Helps in better glycemic control
